CAMBRIDGE, Mass. and NEW YORK, Sept. 05, 2023 Black Diamond Therapeutics, Inc. , a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 1,040,000 shares, a decline of 67.3% from the July 15th total of 3,180,000 shares. Based on an average trading volume of 4,090,000 shares, the days-to-cover […]
Black Diamond Therapeutics, Inc (NASDAQ:BDTX) Sees Large Drop in Short Interest themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Piper Sandler initiated coverage on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a report released on Friday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $11.00 price objective on the stock. Other research analysts have also recently issued research reports about the stock. Wedbush upgraded shares of Black […]